Xenon Gas Protects the Brain After Head Injury

Treatment with xenon gas after a head injury reduces the extent of brain damage, according to a study in mice.

Head injury is the leading cause of death and disability in people aged under 45 in developed countries, mostly resulting from falls and road accidents. The primary injury caused by the initial mechanical force is followed by a secondary injury which develops in the hours and days afterwards. This secondary injury is largely responsible for patients’ mental and physical disabilities, but there are currently no drug treatments that can be given after the accident to stop it from occurring.

Scientists at Imperial College London found that xenon, given within hours of the initial injury, limits brain damage and improves neurological outcomes in mice, both in the short term and long term. The findings, published in the journal Critical Care Medicine, could lead to clinical trials of xenon as a treatment for head injury in humans.

Although xenon is chemically inert, this does not mean it is biologically inactive. Xenon has been known to have general anaesthetic properties since the 1950s. Previous studies at Imperial have found that xenon can protect brain cells from mechanical injury in the lab, but this new study is the first time such an effect has been shown in live animals, a vital step before any new treatments can be tested in humans.

The image shows the outline of a human head. The brain is highlighted in orange. Above the head is a Xe element tab, as if taken from the periodic table.
Previous studies at Imperial have found that xenon can protect brain cells from mechanical injury in the lab, but this new study is the first time such an effect has been shown in live animals, a vital step before any new treatments can be tested in humans. Credit Imperial College London.

Mice were anaesthetised before having a controlled mechanical force applied to the brain. Some were then treated with xenon at different concentrations and at different times after injury.

Mice treated with xenon performed better in tests assessing their neurological deficits, such as movement and balance problems, in the days after injury and after one month. They also had less brain damage, even if treatment was delayed up to three hours after the injury.

Dr Robert Dickinson from the Department of Surgery and Cancer at Imperial College London, who led the study, said: “After a blow to the head, most of the damage to the brain doesn’t occur immediately but in the hours and days afterwards. At present we have no specific drugs to limit the spread of the secondary injury, but we think that is the key to successful treatment.

“This study shows that xenon can prevent brain damage and disability in mice, and crucially it’s effective when given up to at least three hours after the injury. It’s feasible that someone who hits their head in an accident could be treated in the hospital or in an ambulance in this timeframe.

“These findings provide crucial evidence to support doing clinical trials in humans.”

Notes about this TBI research

The research was funded by the European Society for Anaesthesiology, the Royal College of Anaesthetists, the British Journal of Anaesthesia, the Medical Research Council and the Fundação para a Ciência e a Tecnologia, Portugal.

Xenon is also being studied as a treatment for babies who experience oxygen deprivation during birth in a clinical trial led by Imperial and the University of Oxford.

Contact: Sam Wong – Imperial College London
Source: Imperial College London press release
Image Source: The image is adapted from the Imperial College London press release
Original Research: Abstract for “Xenon Improves Neurologic Outcome and Reduces Secondary Injury Following Trauma in an In Vivo Model of Traumatic Brain Injury” by Campos-Pires, Rita MD; Armstrong, Scott P. PhD; Sebastiani, Anne MD; Luh, Clara PhD; Gruss, Marco MD; Radyushkin, Konstantin MD; Hirnet, Tobias; Werner, Christian MD, PhD; Engelhard, Kristin MD, PhD; Franks, Nicholas P. PhD; Thal, Serge C. MD; and Dickinson, Robert PhD in Critical Care Medicine. Published online September 3 2014 doi:10.1097/CCM.0000000000000624

Share this Neurology News
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.